Etoricoxib  is a chemical compound, member of the bipyridine class.

It appears in the form of a whitish powder.

Medical

Etoricoxib fulfils the role of a non-steroidal anti-inflammatory drug (NSAID) in that it is able to inhibit the process of being used as a painkiller and anti-inflammatory cyclooxygenase (COX), thus reducing the production of prostaglandins and thromboxane, which are involved in platelet function, gastrointestinal mucosal defence mechanisms and the regulation of renal blood flow.  Of the two COX isoforms (COX-1 and COX-2), COX-2 is not only responsible for the production of prostaglandins that regulate pain and inflammation mechanisms, but also determines the pain-relieving and anti-inflammatory effect of NSAIDs. In addition, it has a higher COX-1 to COX-2 selectivity ratio than other cox-2 selective NSAIDs and lower risk of gastrointestinal toxicity.

It is indicated for the treatment of psoriatic arthritis, rheumatoid arthritis, chronic low back pain, osteoarthritis, ankylosing spondylitis, acute pain and gout (1).

In post-cardiac surgery patients, Etoricoxib has also been used to treat pericardial effusion (2) and patients treated with Etoricoxib had a lower incidence of hypoxia during hospitalisation for type B aortic dissection undergoing endovascular aortic repair (3).

Heterotopic Ossification. Winkler's study (4) shows an equal efficiency of etoricoxib compared to diclofenac confirming the good efficacy of etoricoxib for the prevention of heterotopic ossification compared to classical methods such as radiotherapy or drug therapy and a lower rate of gastrointestinal bleeding compared to classical NSAIDs.

The efficacy of etoricoxib in extremely elderly patients with chronic pain has also been demonstrated by limiting impairment of walking, depression and anxiety, which are common consequences of persistent pain.

Safety

Datasheet   msds (fishersci.com) 

This study documented seven cases of fixed drug eruption induced by etoricoxib, with a diagnosis based on clinical presentation (5).

For more information:   Etoricoxib studies

Appearance	Off-white powder
Boiling Point	510.0±50.0°C at 760 mmHg
Melting Point	134-135°C
Flash Point	262.2±30.1°C
Density	1.3±0.1 g/cm3
PSA	68.30000
LogP	2.21
Refraction Index	1.601
Vapor Pressure	0.0±1.3 mmHg at 25°C
Storage	-20°C Freezer
Safety

• Molecular Formula  C₁₈H₁₅ClN₂O₂S
• Molercular Weight     358.8
• Exact Mass   358.054260
• CAS   202409-33-4
• UNII    WRX4NFY03R
• EC Number   682-421-5
• DSSTox Substance ID  DTXSID3046457
• IUPAC  5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
• InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3 
• InChl Key      MNJVRJDLRVPLFE-UHFFFAOYSA-N
• SMILES   CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
• MDL number  MFCD06797512
• PubChem Substance ID    329753738
• ChEBI  6339
• Beilstein      8073797
• NACRES NA.24   
• NCI  C52188
• SCHEMBL  4680

Synonyms

• 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
• 5-Chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine
• Arcoxia®
• Etoricoxibe
• Nucoxia
• Etropain
• Tauxib
• Torcoxia
• Algix
• Etoxib
• 2,3'-Bipyridine, 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-

References_______________________________________________________________________

(1) Lories RJ. Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1599-608. doi: 10.1517/17425255.2012.741120.

(2) McNamara, N., Ibrahim, A., Satti, Z., Ibrahim, M., & Kiernan, T. J. (2019). Acute pericarditis: a review of current diagnostic and management guidelines. Future Cardiology, 15(02), 119-126.

(3) Liao H, Ou S, Dong X, Liu J, Xiao C. Association of Etoricoxib treatment and incident hypoxia in patients with aortic dissection undergoing endovascular aortic repair. Biomed Pharmacother. 2021 Jul;139:111625. doi: 10.1016/j.biopha.2021.111625. 

(4) . Winkler S, Springorum HR, Vaitl T, Handel M, Barta S, Kehl V, Craiovan B, Grifka J. Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac. Int Orthop. 2016;40:673–680. doi: 10.1007/s00264-015-3077-z. 

(5) Martínez Antón MD, Galán Gimeno C, Sánchez de Vicente J, Jáuregui Presa I, Gamboa Setién PM. Etoricoxib-induced fixed drug eruption: Report of seven cases. Contact Dermatitis. 2021 Mar;84(3):192-195. doi: 10.1111/cod.13659.